The clinical test to evaluate the effective and safety dosage of dantrolene for the treatment of ventricular tachycardia in patients with heart disease

The clinical test to evaluate the effective and safety dosage of dantrolene for the treatment of ventricular tachycardia in patients with heart disease - dantrolene study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004346

Enrollment

Registered

2010-10-15

Start date

2010-10-01

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventricular tachycardia (CPVT, ARVC, Heart failure)

Interventions

dantrolene

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: COPD muscle dystrophy patients with hepatic disease

Design outcomes

Primary

Measure	Time frame
to investigate the effective and safety dosage of dantrolene for the treatment of ventricular tachycardia in patients with heart disease	—

Countries

Japan

Contacts

Public ContactShigeki Kobayashi

Yamaguchi University Department of Medicine and Clinical Science

0836-22-2248

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026